Skip to main content
Top
Published in: Supportive Care in Cancer 12/2019

01-12-2019 | Original Article

The role of patient-reported outcomes in outpatients receiving active anti-cancer treatment: impact on patients’ quality of life

Authors: Chiara Baratelli, Carmela Giovanna Cleopatra Turco, Gaetano Lacidogna, Elisa Sperti, Francesca Vignani, Donatella Marino, Clizia Zichi, Emmanuele De Luca, Marco Audisio, Daniela Ballaminut, Annalisa Bellezza, Paola Chiotto, Giovanna Ciriolo, Rossella Comite, Fulvia Codegone, Santina Florio, Luisa Fusco, Laura Polimeno, Donatella Pozzi, Eliana Zilio, Sabrina Terzolo, Massimo Di Maio

Published in: Supportive Care in Cancer | Issue 12/2019

Login to get access

Abstract

Introduction

Patient-reported outcomes (PROs) are the gold standard to describe subjective symptoms. Nurses can be successfully involved in collecting symptom information, because of their direct relationship with the patient. In order to improve clinical management of outpatients receiving active anti-cancer treatment, we introduced in routine clinical practice an assessment of patient-reported symptoms and toxicities, starting from January 2018. Our hypothesis was that this could help to better control symptoms, improving patients’ quality of life (QoL).

Methods

Eligible patients were receiving an active anti-cancer treatment, as outpatients. Patients included in the control group (treated in 2017) underwent “usual” visits (group A), while patients treated in 2018, before each visit received a questionnaire by a dedicated nurse, in order to provide information about symptoms and toxicities (group B). Primary objective was the comparison of QoL changes, measured by EORTC QLQ-C30.

Results

A total of 211 patients have been analyzed (119 group A; 92 group B). After 1 month, mean change from baseline of global QoL was − 1.68 in group A and + 2.54 in group B (p = 0.004, effect size 0.20). Group B showed significantly better mean changes for fatigue, pain, and appetite loss. Proportion of patients obtaining a clinically significant improvement in global QoL score was higher in group B (32.6%) compared to group A (19.3%, p = 0.04). Patients’ satisfaction with questionnaire was high.

Conclusion

Introduction of PROs in clinical practice, thanks to an active role of nurses, was feasible, produced high patients’ satisfaction and a significant QoL improvement, compared to the traditional modality of visit.
Appendix
Available only for authorised users
Literature
2.
go back to reference Basch E, Bennett A, Pietanza MC (2011) Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst 103:1808–1810CrossRef Basch E, Bennett A, Pietanza MC (2011) Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst 103:1808–1810CrossRef
3.
go back to reference Petersen MA, Larsen H, Pedersen L, Sonne N, Groenvold M (2006) Assessing health-related quality of life in palliative care: comparing patient and physician assessments. Eur J Cancer 42:1159–1166CrossRef Petersen MA, Larsen H, Pedersen L, Sonne N, Groenvold M (2006) Assessing health-related quality of life in palliative care: comparing patient and physician assessments. Eur J Cancer 42:1159–1166CrossRef
4.
go back to reference Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30. J Clin Oncol 22:3485–183490CrossRef Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30. J Clin Oncol 22:3485–183490CrossRef
5.
go back to reference Di Maio M, Basch E, Bryce J, Perrone F (2016) Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol 13(5):319–325CrossRef Di Maio M, Basch E, Bryce J, Perrone F (2016) Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol 13(5):319–325CrossRef
8.
go back to reference Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D (2006) Patient versus clinician symptom reporting using the National Cancer Institute common terminology criteria for adverse events: results of a questionnaire based study. Lancet Oncol 7:903–909CrossRef Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D (2006) Patient versus clinician symptom reporting using the National Cancer Institute common terminology criteria for adverse events: results of a questionnaire based study. Lancet Oncol 7:903–909CrossRef
9.
go back to reference Grossman SA, Sheidler VR, Swedeen K, Mucenski J, Piantadosi S (1991) Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manag 6:53–57CrossRef Grossman SA, Sheidler VR, Swedeen K, Mucenski J, Piantadosi S (1991) Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manag 6:53–57CrossRef
10.
go back to reference Cirillo M, Venturini M, Ciccarelli L, Coati F, Bortolami O, Verlato G (2009) Clinician versus nurse symptom reporting using the National Cancer Institute-common terminology criteria for adverse events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire. Ann Oncol 20:1929–1935CrossRef Cirillo M, Venturini M, Ciccarelli L, Coati F, Bortolami O, Verlato G (2009) Clinician versus nurse symptom reporting using the National Cancer Institute-common terminology criteria for adverse events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire. Ann Oncol 20:1929–1935CrossRef
11.
go back to reference Di Maio M, Gallo C, Leighl NB et al (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915CrossRef Di Maio M, Gallo C, Leighl NB et al (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915CrossRef
12.
go back to reference Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318(2):197–198CrossRef Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318(2):197–198CrossRef
13.
go back to reference Judson TJ, Bennett AV, Rogak LJ, Sit L, Barz A, Kris MG, Hudis CA, Scher HI, Sabattini P, Schrag D, Basch E (2013) Feasibility of long-term patient self-reporting of toxicities from home via the internet during routine chemotherapy. J Clin Oncol 31(20):2580–2585CrossRef Judson TJ, Bennett AV, Rogak LJ, Sit L, Barz A, Kris MG, Hudis CA, Scher HI, Sabattini P, Schrag D, Basch E (2013) Feasibility of long-term patient self-reporting of toxicities from home via the internet during routine chemotherapy. J Clin Oncol 31(20):2580–2585CrossRef
14.
go back to reference Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565CrossRef Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565CrossRef
15.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRef Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRef
16.
go back to reference Fayers P, Aaronson NK, Bjordal K et al (1999) on behalf of the EORTC Quality of Life Study Group EORTC QLQ-C30 Scoring Manual, 2nd edn. EORTC, Brussels (Belgium) Fayers P, Aaronson NK, Bjordal K et al (1999) on behalf of the EORTC Quality of Life Study Group EORTC QLQ-C30 Scoring Manual, 2nd edn. EORTC, Brussels (Belgium)
17.
go back to reference Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139–144CrossRef Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139–144CrossRef
18.
go back to reference Sperti E, Di Maio M (2017) Outcomes research: integrating PROs into the clinic - overall survival benefit or not, it's worth the trouble. Nat Rev Clin Oncol 14(9):529–530CrossRef Sperti E, Di Maio M (2017) Outcomes research: integrating PROs into the clinic - overall survival benefit or not, it's worth the trouble. Nat Rev Clin Oncol 14(9):529–530CrossRef
19.
go back to reference Howell D, Molloy S, Wilkinson K, Green E, Orchard K, Wang K, Liberty J (2015) Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol 26:1846–1858CrossRef Howell D, Molloy S, Wilkinson K, Green E, Orchard K, Wang K, Liberty J (2015) Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol 26:1846–1858CrossRef
20.
go back to reference Valderas JM, Kotzeva A, Espallargues M, Guyatt G, Ferrans CE, Halyard MY, Revicki DA, Symonds T, Parada A, Alonso J (2008) The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literature. Qual Life Res 17:179–193CrossRef Valderas JM, Kotzeva A, Espallargues M, Guyatt G, Ferrans CE, Halyard MY, Revicki DA, Symonds T, Parada A, Alonso J (2008) The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literature. Qual Life Res 17:179–193CrossRef
21.
go back to reference Chen J, Ou L, Hollis SJ (2013) A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res 13(211) Chen J, Ou L, Hollis SJ (2013) A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res 13(211)
22.
go back to reference Kotronoulas G, Kearney N, Maguire R, Harrow A, di Domenico D, Croy S, MacGillivray S (2014) What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol 32:1480–1501CrossRef Kotronoulas G, Kearney N, Maguire R, Harrow A, di Domenico D, Croy S, MacGillivray S (2014) What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol 32:1480–1501CrossRef
23.
go back to reference Stover AM, Basch EM (2016) Implementation of symptom questionnaires into oncology workflow. J Oncol Pract 12(10):859–862CrossRef Stover AM, Basch EM (2016) Implementation of symptom questionnaires into oncology workflow. J Oncol Pract 12(10):859–862CrossRef
Metadata
Title
The role of patient-reported outcomes in outpatients receiving active anti-cancer treatment: impact on patients’ quality of life
Authors
Chiara Baratelli
Carmela Giovanna Cleopatra Turco
Gaetano Lacidogna
Elisa Sperti
Francesca Vignani
Donatella Marino
Clizia Zichi
Emmanuele De Luca
Marco Audisio
Daniela Ballaminut
Annalisa Bellezza
Paola Chiotto
Giovanna Ciriolo
Rossella Comite
Fulvia Codegone
Santina Florio
Luisa Fusco
Laura Polimeno
Donatella Pozzi
Eliana Zilio
Sabrina Terzolo
Massimo Di Maio
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 12/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-04777-2

Other articles of this Issue 12/2019

Supportive Care in Cancer 12/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine